GDUFA III: Convening Enhanced Mid-Cycle Meeting Will Cost Sponsors
Executive Summary
Requesting the new meeting type for an ANDA assessment will trigger a goal date extension with another possible should an unsolicited application amendment also be necessary.
You may also be interested in...
ANDA Sponsors Given More Paperwork
Optional checklists will help ensure submissions have all the required information.
US FDA Hoping To Spur More ANDA Pre-Submission Meetings During GDUFA III
The FDA believes conducting a pre-submission meeting when a complex generic application has unusual elements can increase the likelihood of a first-cycle approval.
Holding ANDA Labeling Review Until Late Cycle Could Minimize Delays From Last-Minute Changes
A GDUFA III adjustment could allow more labeling changes during the review cycle and reduce assessment cycles.